World Congress on Gynecology & Obstetrics October 22-23, 2021 Tokyo, Japan

Biography:

Professor, Benha University Hospital, Egypt

Abstract:

Background: The successful use of PRP in regenerative medicine has led investigators to study its effect in the treatment of conditions like decreased ovarian reserve, poor responders, premature ovarian insufficiency, thin endometrium and Aschermann syndrome

Objective: To review the uses of PRP (intraovarian & intrauterine) in reproductive medicine.

Methods: A literature search for English articles related to the uses of PRP in reproductive medicine, including articles published in PubMed, from 2000 to August 2021.

Results: For intraovarian PRP: 17 studies were found: No RCT. Studies were classified according to indication. (1) For diminished ovarian reserve: 6 studies including 369 patients. (2). For poor responders: 3 case series studies including 41 patients with an improvement in ovarian response. (3) For premature ovarian insufficiency: 8 studies including 373 patients. Ovarian reserve markers were the outcome of all studies with conflicting results. LBR was not determined in the majority of studies. For Intrauterine PRP: 15 studies were found. Studies were classified according to indication. 1. For thin endometrium 10 studies including only 3 RCT with an improvement in endometrial thickness. 2. Aschermann syndrome: 4 studies (2 case series & 2 comparative studies) including 51 patients without significant benefit. 3. Chronic endometritis, one case report with successful treatment

Conclusion: Intraovarian PRP for diminished ovarian reserve, poor ovarian response, or POI is still experimental. Intrauterine PRP for thin endometrium is promising. Well-designed, large RCTS to confirm its efficacy and safety are required.

Biography:

Prof. Dr. Panayiotis Zavos, Ed.S., Ph.D., Director & Chief of Andrology and Theodora  Zavos, Visiting Scholar, Andrology Institute of America, Lexington, Kentucky USA.

Abstract:

Male infertility is linked to some viral infections including human papillomavirus (HPV), herpes simplex viruses (HSV) and human immunodeficiency viruses (HIVs). As for acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), its effects on worldwide declines in sperm count and fertility have not been researched thoroughly. With the recent increase of viral infections due to the pandemic, the potential negative impacts that SARS-CoV-2 will have on male reproductive organs and male fertility have raised countless concerns.

This presentation aims to discuss the possible effects that the SARS-CoV-2 pandemic may have on an already declining male reproductive success while integrating the results of recent studies focusing on similar topics. Furthermore, it will also mention the future implications that come with a more infertile population. Within the various articles studied, it has become apparent that the SARS-CoV-2 pandemic has and will only decrease men’s sperm quality further. These findings became apparent through the study of oxidative stress established through the sperm’s production of reactive oxygen species and the COVID-19 virus’ ability to attack human spermatozoa produced in the testes due to expression of the ACE2 gene. As for the decline in male fertility prior to the SARS-CoV-2 pandemic, there are many other factors to be discussed, some of which include tobacco consumption, alcoholism, diet, electronics, and higher rates of testicular cancer. Would the Covid-19 have similar effects on the ovary and overall female reproductive performance?

Biography:

Dr. Urmila Diwekar is the President of Stochastic Research Technologies LLC and the president of the Vishwamitra Research, a non-profit research institute that she founded to pursue multidisciplinary research and development.  From 2002-2004, she was a Professor at the University of Illinois at Chicago.    From 1991-2002 she was on the faculty of the Carnegie Mellon University. She is the author of more than 190 peer-reviewed research papers, 15 book chapters, 7 books, 3 software packages, and has given over 400 presentations and seminars, and has chaired numerous sessions in national and international meetings.  She has been the principal advisor to 45 Ph.D. and M.S. students, and has advised 15 post-doctoral fellows and researchers.   She is fellow of AIMBE and AIChE.

Abstract:

Superovulation is a drug-induced method to enable multiple ovulation per menstrual cycle and key component towards a successful IVF cycle. Although there are the general guidelines for dosage, the dose is not optimized for each patient, and complications, such as overstimulation, can occur. To overcome the shortcomings of this general system, a mathematical procedure and a decision support tool is developed which can provide a customized model of this stage regarding the size distribution of follicles obtained per cycle as a function of the chemical interactions of the drugs used and the conditions imposed on the patient during the cycle.  Uncertainty and risk are modeled and included in optimal drug dosage decisions. This paper describes the theory, model, the optimal control procedure, and the decision support tool for improving outcomes of IVF treatment for all the four protocols used in real practice. The validation of the procedure is performed using clinical data from more than 100 patients previously undergone IVF cycles. Customized patient-specific model parameters are obtained by using initial two-day data for each patient and validated. The models are then used for predicting the customized optimal drug dosage for each patient. Two clinical trials were conducted in India. The results from the trials show that the dosage predicted by using the model is 40% less than the suggestion made by the IVF clinicians. The testing and monitoring requirements for patients using optimized drug dosage is reduced by 72%.

Biography:

Kurashiki Heisei Hospital gynecology department manager Japan Obstetrics and Gynecology Association Specialist Doctor of Osteoporosis Society.

Abstract:

Bone is not just a pillar of the body, but an important organ that controls hematopoiesis and metabolism. Bone was originally a hematopoietic and metabolic organ made of cartilage until the acquisition of hydroxyapatite. Human bone is an organ that is constantly being scraped and build and renewed. This bone health also supports a woman's lifelong quality of life. Hormone therapy is used for dysmenorrhea, endometriosis, menorrhagia, uterine fibroids, etc., but the effects on bone are described separately for puberty and maturity. Bone growth, especially during adolescence, is an important period of elongation and formation. We propose from the evidence the optimal hormone therapy for this period. In addition to hormone therapy, iron preparations are another treatment for menorrhagia. Administration of iron is very effective in correcting anemia due to menorrhagia, but on the other hand, it presents a decrease in bone mineral density due to hypophosphatemia. We will consider the effects on bones of long-term treatment of anemia due to menorrhagia by administration of iron preparations. Finally, the decrease in bone density that begins immediately after menopause causes postmenopausal osteoporosis in old age, which causes a decrease in QOL in women. Therefore, it is important to pay attention to bone health immediately after menopause, not only to alleviate menopausal symptoms, but also to prevent bone loss. I will describe TSEC, which is the newest hormone therapy.

The ovaries and uterus are short-lived organs, but long-lived organs such as bones reach menopause and continue to support them until their longevity. For a woman's long life, menopause is the middle of her life. We consider from a gynecological point of view so that women can live long and prosperous.

Biography:

All India Institute of Medical Sciences India

Abstract:

Objectives: Compare serum uric acid and calcium levels among normotensive and hypertensive pregnant women, to compare maternal and perinatal outcomes in two groups.

Materials and methods: Prospective case control study was conducted after ethical approval in Obstetrics and Gynecology department of rural tertiary care center of Northern India, over seven months. Total 220 antenatal women ≥34 weeks of gestation with 110 cases having hypertensive disorder of pregnancy and 110 controls with normal blood pressure were compared for maternal uric acid and calcium levels and maternal, perinatal outcomes.

Results: Mean ± SD values of uric acid and calcium in control group was 4.42 ± 1.42 mg/dl and 8.94 ± 0.6 mg/dl, whereas in cases they were 6.8 ± 2.72 mg/dl and 8.61 ± 0.78 mg/dl (p < 0.05). Induced labor followed by lower segment caesarean section was the most common mode of delivery in hypertensive cases, whereas, in controls, the majority had spontaneous onset of labor and delivered vaginally (p < 0.05). Hypertensive women with higher uric acid and lower calcium had adverse perinatal outcome as compared to controls (p < 0.05). Mean ± SD of neonatal birth weight in controls was 2.81 ± 0.295 Kg and in cases 2.56 ± 0.421 Kg. Neonatal birth weight was significantly associated with maternal uric acid than calcium in hypertensive women. Cases with hyperuricemia and low calcium levels had adverse overall outcome as compared to controls.

Conclusion: Maternal hyperuricemia and hypocalcemia was associated with adverse maternal, perinatal outcomes in women with hypertensive disorder of pregnancy as compared to healthy normotensive women.

Biography:

Huang Wei Ling, born in Taiwan, raised and graduated in medicine in Brazil, specialist in infectious and parasitic diseases, a General Practitioner and Parenteral and Enteral Medical Nutrition Therapist. Once in charge of the Hospital Infection Control Service of the City of Franca’s General Hospital, she was responsible for the control of all prescribed antimicrobial medication and received an award for the best paper presented at the Brazilian Hospital Infection Control Congress in 1998. 

Abstract:

Introduction: COVID-19 is a disease caused by SARS-CoV-2 infection that is affecting all kinds of populations nowadays, independent of age, gender, co-morbidities or not and also, can affect pregnant women. There were some deaths reported in some countries of pregnant women after COVID-19 vaccination and in Brazil, there is a rule to prohibit the vaccination of pregnant women after these incidents.

Purpose; to demonstrate that pregnant women has chakras’ energy deficiencies (reduced immune system), as the same deficiency in the entire population nowadays, classifying them as immune-depressant and not immune-competent, demonstrated in the article Energy Alterations and Chakras’ Energy Deficiencies and Propensity to SARS-CoV-2 Infection.

Methods: thought one case report of pregnant patient with chakras’ energy centers deficient in energy in all six of seventh chakras’ energy centers.

Results: the patients was orientate to begin the intake of medications in highly concentrations  such as homeopathies according to the theory Constitutional Homeopathy of the Five Elements Based on Traditional Chinese Medicine and crystal –based medications to replenish this energies to fortify the immune system and also, the intake of SARS-CoV-2 nosodium ( homeopathy medications using patients with SARS-CoV-2 secretions to do this medications in a very high diluted ) to  prevent the acquisition of SARS-CoV-2 infection.

Conclusion: pregnant patient has low energy in the chakras’ energy centers and the treatment of this condition before , during and after the pregnancy is of paramount importance to prevent SARS-CoV-2 infection, fortifying the immune system of all these patients when the use of vaccine is not recommended or has any side effect that can cause doubt in the prescription of this way of prevention and other forms of preventions should be sought, fortifying the energy and the immune system of pregnant and no pregnant women nowadays.